Using MRI to assess aortic disease in Marfan syndrome patients
Towards Optimal Treatment of Marfan Syndrome
This study is testing new MRI techniques to see how well they can help doctors understand the severity of aortic disease in people with Marfan syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 4 sites (Nijmegen, Gelderland and 3 other locations) |
| Trial ID | NCT05944614 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of new magnetic resonance imaging (MRI) techniques as biomarkers for assessing the severity of aortic disease in individuals diagnosed with Marfan syndrome. The study will involve patients aged 18 to 50 who have a known FBN1 mutation, utilizing MRI examinations to gather data on aortic conditions. By analyzing the results, researchers hope to improve the understanding of aortic disease progression in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 50 with Marfan syndrome and a confirmed FBN1 mutation.
Not a fit: Patients with contraindications for MRI or those with a history of aortic disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better monitoring and management of aortic disease in patients with Marfan syndrome.
How similar studies have performed: While the use of MRI in assessing aortic disease is established, this specific application in Marfan syndrome is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * MFS patients with a known FBN1 mutation * Between 18-50 years of age Exclusion Criteria: * Contraindication for MR imaging * Mental retardation * Pregnancy, or planned pregnancy during study period Additional exclusion criteria healthy controls: - History of aorta disease
Where this trial is running
Nijmegen, Gelderland and 3 other locations
- Radboud University Medical Center — Nijmegen, Gelderland, Netherlands (Not_yet_recruiting)
- Amsterdam UMC, location AMC — Amsterdam, Meibergdreef 9, Netherlands (Recruiting)
- Leiden University Medical Center — Leiden, Noord-Holland, Netherlands (Not_yet_recruiting)
- University Medical Center Groningen — Groningen, Netherlands (Not_yet_recruiting)
Study contacts
- Principal investigator: Pim Ooij, PhD — Amsterdam UMC
- Study coordinator: Daan Bosshardt, MD
- Email: d.bosshardt@amsterdamumc.nl
- Phone: +31 (0) 20 566 9111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.